BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 18076022)

  • 1. Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis.
    Thorpe JA; Christian PA; Schwarze SR
    Prostate; 2008 Feb; 68(2):200-9. PubMed ID: 18076022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.
    Ganten TM; Koschny R; Haas TL; Sykora J; Li-Weber M; Herzer K; Walczak H
    Hepatology; 2005 Sep; 42(3):588-97. PubMed ID: 16037944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
    Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
    Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
    An J; Sun YP; Adams J; Fisher M; Belldegrun A; Rettig MB
    Clin Cancer Res; 2003 Oct; 9(12):4537-45. PubMed ID: 14555528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib.
    Emanuele S; Lauricella M; Carlisi D; Vassallo B; D'Anneo A; Di Fazio P; Vento R; Tesoriere G
    Apoptosis; 2007 Jul; 12(7):1327-38. PubMed ID: 17351739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).
    Yin D; Zhou H; Kumagai T; Liu G; Ong JM; Black KL; Koeffler HP
    Oncogene; 2005 Jan; 24(3):344-54. PubMed ID: 15531918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted induction of apoptosis via TRAIL and cryoablation: a novel strategy for the treatment of prostate cancer.
    Clarke DM; Robilotto AT; VanBuskirk RG; Baust JG; Gage AA; Baust JM
    Prostate Cancer Prostatic Dis; 2007; 10(2):175-84. PubMed ID: 17297503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
    Yerlikaya A; Erin N
    Int J Mol Med; 2008 Dec; 22(6):817-23. PubMed ID: 19020781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethanolic extract of Brazilian green propolis sensitizes prostate cancer cells to TRAIL-induced apoptosis.
    Szliszka E; Zydowicz G; Janoszka B; Dobosz C; Kowalczyk-Ziomek G; Krol W
    Int J Oncol; 2011 Apr; 38(4):941-53. PubMed ID: 21286663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dietary flavonol fisetin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells.
    Szliszka E; Helewski KJ; Mizgala E; Krol W
    Int J Oncol; 2011 Oct; 39(4):771-9. PubMed ID: 21743964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Akt signaling by the lignan matairesinol sensitizes prostate cancer cells to TRAIL-induced apoptosis.
    Peuhu E; Rivero-Müller A; Stykki H; Torvaldson E; Holmbom T; Eklund P; Unkila M; Sjöholm R; Eriksson JE
    Oncogene; 2010 Feb; 29(6):898-908. PubMed ID: 19935713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Proteasome inhibitors: induction of apoptosis as new therapeutic option in prostate cancer].
    Tahmatzopoulos A; Gudegast C; Stöckle M; Wullich B; Unteregger G; Zwergel U; Zwergel T
    Aktuelle Urol; 2004 Nov; 35(6):491-6. PubMed ID: 15526229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the ubiquitin-proteasome system sensitizes TRAIL-resistant prostate cancer cells by up-regulation of death receptor 5.
    Lee YJ; Seol JW; Jeong JK; Moon MH; Park SY
    Mol Med Rep; 2011; 4(6):1255-9. PubMed ID: 21850375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
    Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
    Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catalytically active Yersinia outer protein P induces cleavage of RIP and caspase-8 at the level of the DISC independently of death receptors in dendritic cells.
    Gröbner S; Adkins I; Schulz S; Richter K; Borgmann S; Wesselborg S; Ruckdeschel K; Micheau O; Autenrieth IB
    Apoptosis; 2007 Oct; 12(10):1813-25. PubMed ID: 17624595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical roles for JNK, c-Jun, and Fas/FasL-Signaling in vitamin E analog-induced apoptosis in human prostate cancer cells.
    Jia L; Yu W; Wang P; Li J; Sanders BG; Kline K
    Prostate; 2008 Mar; 68(4):427-41. PubMed ID: 18196534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of proteasome activity sensitizes human granulosa tumor cells to TRAIL-induced cell death.
    Woods DC; Liu HK; Nishi Y; Yanase T; Johnson AL
    Cancer Lett; 2008 Feb; 260(1-2):20-7. PubMed ID: 18031928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors.
    Schimmer AD; Thomas MP; Hurren R; Gronda M; Pellecchia M; Pond GR; Konopleva M; Gurfinkel D; Mawji IA; Brown E; Reed JC
    Cancer Res; 2006 Feb; 66(4):2367-75. PubMed ID: 16489043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts.
    Chen D; Cui QC; Yang H; Barrea RA; Sarkar FH; Sheng S; Yan B; Reddy GP; Dou QP
    Cancer Res; 2007 Feb; 67(4):1636-44. PubMed ID: 17308104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.